FDA要求在糖皮质激素注射剂标签中加入新的警告

2014-04-25 fyc5078 丁香园

FDA称,注射式糖皮质激素现在必须增加一个新的标签警告,即硬膜外腔注射的严重副作用风险包括死亡、中风及永久性失明和瘫痪。 FDA在审查大量的医学文献报道及其自身的不良事件数据库之后,决定糖皮质激素注射剂类药物标签中需要加入这样的警告。 “严重不良事件包括死亡、脊髓梗死、截瘫、四肢瘫痪、皮质盲、中风、癫痫、神经损伤和脑水肿,”FDA在宣布的这项警告时表示道。 “很多情况与皮质类固醇注射相关,皮

FDA称,注射式糖皮质激素现在必须增加一个新的标签警告,即硬膜外腔注射的严重副作用风险包括死亡、中风及永久性失明和瘫痪。


FDA在审查大量的医学文献报道及其自身的不良事件数据库之后,决定糖皮质激素注射剂类药物标签中需要加入这样的警告。

“严重不良事件包括死亡、脊髓梗死、截瘫、四肢瘫痪、皮质盲、中风、癫痫、神经损伤和脑水肿,”FDA在宣布的这项警告时表示道。

“很多情况与皮质类固醇注射相关,皮质类固醇注射后数分钟到48小时内有不良事件发生。在某些情况下,神经系统不良事件的诊断可通过磁共振成像或断层扫描得到证实。研究报道称,很多患者无法从这些不良事件中恢复。”

总之,FDA称这些不良事件虽然很少,但相当严重。修改后的标签可使卫生保健提供者在用药前与患者讨论相关的风险,指导他们观察不良神经系统影响,如失明、麻木或刺痛感、严重头痛或癫痫发作等。

FDA强调,该警告与2012年类固醇使用相关的真菌污染问题无关。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1701122, encodeId=68c91e01122e3, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Sep 13 12:37:00 CST 2014, time=2014-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371270, encodeId=95ff13e12708a, content=<a href='/topic/show?id=d984649e455' target=_blank style='color:#2F92EE;'>#注射剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64974, encryptionId=d984649e455, topicName=注射剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5380325, createdName=zchen, createdTime=Sun Apr 27 00:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600224, encodeId=faf6160022458, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Sun Apr 27 00:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613806, encodeId=ffc5161380688, content=<a href='/topic/show?id=1ef6668381c' target=_blank style='color:#2F92EE;'>#激素注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66838, encryptionId=1ef6668381c, topicName=激素注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df0e19436042, createdName=肉我只吃一口, createdTime=Sun Apr 27 00:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1701122, encodeId=68c91e01122e3, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Sep 13 12:37:00 CST 2014, time=2014-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371270, encodeId=95ff13e12708a, content=<a href='/topic/show?id=d984649e455' target=_blank style='color:#2F92EE;'>#注射剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64974, encryptionId=d984649e455, topicName=注射剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5380325, createdName=zchen, createdTime=Sun Apr 27 00:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600224, encodeId=faf6160022458, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Sun Apr 27 00:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613806, encodeId=ffc5161380688, content=<a href='/topic/show?id=1ef6668381c' target=_blank style='color:#2F92EE;'>#激素注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66838, encryptionId=1ef6668381c, topicName=激素注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df0e19436042, createdName=肉我只吃一口, createdTime=Sun Apr 27 00:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=)]
    2014-04-27 zchen
  3. [GetPortalCommentsPageByObjectIdResponse(id=1701122, encodeId=68c91e01122e3, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Sep 13 12:37:00 CST 2014, time=2014-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371270, encodeId=95ff13e12708a, content=<a href='/topic/show?id=d984649e455' target=_blank style='color:#2F92EE;'>#注射剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64974, encryptionId=d984649e455, topicName=注射剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5380325, createdName=zchen, createdTime=Sun Apr 27 00:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600224, encodeId=faf6160022458, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Sun Apr 27 00:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613806, encodeId=ffc5161380688, content=<a href='/topic/show?id=1ef6668381c' target=_blank style='color:#2F92EE;'>#激素注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66838, encryptionId=1ef6668381c, topicName=激素注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df0e19436042, createdName=肉我只吃一口, createdTime=Sun Apr 27 00:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1701122, encodeId=68c91e01122e3, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Sep 13 12:37:00 CST 2014, time=2014-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371270, encodeId=95ff13e12708a, content=<a href='/topic/show?id=d984649e455' target=_blank style='color:#2F92EE;'>#注射剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64974, encryptionId=d984649e455, topicName=注射剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5380325, createdName=zchen, createdTime=Sun Apr 27 00:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600224, encodeId=faf6160022458, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Sun Apr 27 00:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613806, encodeId=ffc5161380688, content=<a href='/topic/show?id=1ef6668381c' target=_blank style='color:#2F92EE;'>#激素注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66838, encryptionId=1ef6668381c, topicName=激素注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df0e19436042, createdName=肉我只吃一口, createdTime=Sun Apr 27 00:37:00 CST 2014, time=2014-04-27, status=1, ipAttribution=)]

相关资讯

百时美丙肝鸡尾酒疗法DCV/ASV III期治愈率达90%

百时美施贵宝(BMS)4月10日公布了丙肝鸡尾酒疗法(daclatasvir+asunaprevir,即DCV+ASV)一项国际性III期研究HALLMARK-DUAL的数据。DCV+ASV是一种实验性全口服、无干扰素、无利巴韦林丙肝治疗方案。该项研究在基因型1b丙型肝炎病毒(HCV)感染者中开展,数据表明,接受DCV+ASV方案治疗后,初治患者组有90%的患者实现SVR12(完成治疗后12周的持

FDA批准奥马珠单抗(Xolair)用于慢性特发性荨麻疹

• 近50%的CIU患者在使用获批剂量的H1-抗组胺药治疗后疗效不佳,对于此类患者Xolair®是目前第一个且唯一一个获美国批准的治疗药物 • CIU在美国以外的地区被称为CSU,这是一种严重的皮肤病,特征表现为慢性瘙痒,荨麻疹和血管性水肿。 • Xolair®获得美国食品药品管理局批准用于治疗CIU的治疗严格依照欧盟批准Xolair®用于CSU的治疗准则

默沙东丙肝鸡尾酒MK-5172/MK-8742初治群体治愈率近100%

默沙东(Merck & Co)4月10日公布了一项正在开展的II期研究(C-WORTHY Study)的额外数据。对初治非肝硬化患者组开展的一项中期分析表明,接受为期12周的MK-5127/MK-8742方案(联合利巴韦林RBV及无RBV)治疗后,MK-5127/MK-8742(无RBV)治疗组有98%(42/43)的患者取得持续病毒学应答(SVR),MK-5127/MK-8742+RBV

解读FDA《互动推广媒介使用指南草案》——药企将全面对接社交媒体

医药行业在利用社交媒体实现经营目标方面远远落后于其他行业,这已经不是什么秘密了。这其中一个很大的原因就在于医药行业一直都没有FDA颁发的明确的指导准则。这个月,FDA颁布了《互动推广媒介使用指南草案》,结束了多年来的猜测,并且最终为行业提供了数字媒体使用方面的主要指南。虽然该指南草案文件目前只是为了征求意见而发布,但是它第一次阐明了实时通信和互动工具和技术(包括社交媒体)(interactiv

FDA扩美敦力CRT适应证

近日,美国食品与药物管理局(FDA)批准了10种美敦力双心室起搏器用于治疗伴有不太严重收缩期心衰和需右室置入起搏器的房室传导阻滞患者。 CRT-D和CRT-P既往仅被批准用于LVEF<35%且QRS间期延长的心衰患者。此次适应证扩展主要基于BLOCK-HF随机试验结果而做出。BLOCK-HF试验共纳入691例伴有一度、二度或三度房室传导阻滞、NYHA分级1~3心衰和LVEF<50%的

BI与礼来向FDA提交Empagliflozin/利格列汀复方药物上市申请

4月14日,勃林格殷格翰与礼来称,美国FDA接受了Empagliflozin和利格列汀复方药物片剂用于2型糖尿病的新药申请(NDA)。 如果获得FDA批准,该复方药物将成为首款将两种明显不同作用机制——一种钠葡萄糖协同转运蛋白-2 (SGLT2)抑制剂和一种二肽基肽酶4(DPP-4)抑制剂——药物组合一起的复方新药。SGLT2抑制剂通过阻止葡萄糖在肾内的重吸收使过多的葡萄糖通过尿排除。DPP-4